Edwards Lifesciences Corporation (EW) Q2 2018 Earnings Results

Edwards Lifesciences Beats on EPS, Stock Down 0.04%

Edwards Lifesciences reported a solid earnings surprise on EPS, which may indicate strong operational performance. However, the stock saw a slight decline of 0.04%, suggesting that investors may have been expecting more comprehensive revenue details or guidance. The lack of revenue data and future guidance could contribute to cautious sentiment among investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.24	N/A	+5.31%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's growth trajectory. They emphasized the importance of their product pipeline and market presence.

Management highlighted strong performance in key product areas.

They noted ongoing investments in innovation and market expansion.

Edwards Lifesciences Beats on EPS, Stock Down 0.04%

Key numbers

Management commentary

Edwards Lifesciences Corporation

More earnings this week

Edwards Lifesciences Beats on EPS, Stock Down 0.04%

Key numbers

Management commentary